1332 — Touyun Biotech Income Statement
0.000.00%
Last trade - 00:00- HK$339.48m
- HK$826.53m
- HK$66.97m
Annual income statement for Touyun Biotech, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | PRESS | PRESS |
| Standards: | HKAS | HKAS | HKAS | — | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 284 | 316 | 199 | 99.6 | 67 |
| Cost of Revenue | |||||
| Gross Profit | 107 | 120 | 56.6 | 37.1 | 18 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 389 | 493 | 464 | 169 | -1.79 |
| Operating Profit | -106 | -178 | -265 | -69.5 | 68.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -123 | -199 | -273 | -79.2 | 47.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -124 | -203 | -273 | -78.8 | 47.6 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -72.9 | -198 | -269 | -88.1 | 26.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -72.9 | -198 | -269 | -88.1 | 26.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.021 | -0.07 | -0.077 | -0.028 | 0.006 |